Key result
In community psychiatric patients treated with antipsychotics, metabolic health worsened over 19 months, with mean BMI increasing from 29.2 to 29.9 kg/m2 (p<0.005), alongside extremely poor metabolic monitoring rates.
Cohort (n=106)
Absolute Event Rate: 29.9% vs 29.2%
p-value: p=<0.005
Community psychiatric patients on antipsychotics have worsening metabolic profiles and alarmingly poor rates of metabolic monitoring despite guideline recommendations.
Metabolic deterioration and monitoring gaps persist in antipsychotic-treated patients; hypothesis-generating for targeted community interventions.
BACKGROUND: Patients with severe mental illness are at increased risk for metabolic and cardiovascular disease. A number of recent guidelines and consensus statements recommend stringent monitoring of metabolic function in individuals receiving antipsychotic drugs. METHODS: We conducted a prospective cohort study of 106 community-treated psychiatric patients from across the diagnostic spectrum from the Northeast of England to investigate changes in metabolic status and monitoring practices for metabolic and cardiovascular disease. We undertook detailed anthropometric and metabolic assessment at baseline and follow-up, and examined clinical notes and hospital laboratory records to ascertain monitoring practices. RESULTS: A high prevalence of undiagnosed and untreated metabolic disease was present at baseline assessment. Mean follow-up time was 599.3 (SD +/- 235.4) days. Body mass index (p < 0.005) and waist circumference (p < 0.05) had significantly increased at follow-up, as had the number of individuals who were either overweight or obese. Fifty-three per cent of individuals had hypertriglyceridemia, and 31% had hypercholesterolemia, but only 7% were receiving lipid-lowering therapy. Monitoring practices were poor. Recording of measures of adiposity occurred in 0% of individuals, and > 50% of subjects had neither blood glucose nor lipids monitored during the follow-up period. CONCLUSION: This cohort has a high prevalence of metabolic disease and heightened cardiovascular risk. Despite the publication of a number of recommendations regarding physical health screening in this population, monitoring rates are poor, and physical health worsened during the follow-up period.
No takes yet. Share an insight, caveat, or question.
Mackin et al. (2007) conducted a cohort in Severe mental illness (n=106). Antipsychotic drugs vs. Baseline was evaluated on Body mass index (kg/m2) (p=<0.005). In community psychiatric patients treated with antipsychotics, metabolic health worsened over 19 months, with mean BMI increasing from 29.2 to 29.9 kg/m2 (p<0.005), alongside extremely poor metabolic monitoring rates.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: